Stocks were indicated higher again on Wednesday, once more proving that investors want in the market either on weakness or when they find new value opportunities. 24/7 Wall St. reviews dozens of analyst reports each day of the week to find new investing and trading ideas for its readers. Some analyst reports cover stocks to buy, and other calls cover stocks to sell or to avoid.
These are this Wednesday’s top analyst upgrades, downgrades and initiations.
Apple Inc. (NASDAQ: AAPL) was added to the prized Conviction Buy List at Goldman Sachs. The price target is $163.00 (versus a $113.69 prior close). Apple’s consensus analyst price target is currently $148.88 and its 52-week trading range is $92.00 to $134.54.
Bluebird Bio Inc. (NASDAQ: BLUE) was started with a Buy rating and was assigned a $165 price target (versus a $79.61 close, after a 6.9% gain) at Goldman Sachs. Bluebird shares were indicated up 5% to $83.70 early Wednesday, and it has a 52-week range of $39.02 to $197.30.
Exxon Mobil Corp. (NYSE: XOM) was downgraded to Underperform from Market Perform at Raymond James. Shares closed at $79.96 Tuesday, and the consensus analyst price target of $83.70 is within a 52-week range of $66.55 to $97.20.
Kinder Morgan Inc. (NYSE: KMI) was maintained as Buy at Goldman Sachs, but the firm removed it from the prized Conviction Buy list. Goldman Sachs also lowered Kinder Morgan’s price target to $29 from $39 (versus a $23.36 close).
Kinross Gold Corp. (NYSE: KGC) was downgraded to Market Perform from Outperform and the price target was cut to $2.50 from $3.00 (versus a $1.75 close) at Raymond James. The consensus price target is $2.58, and the 52-week range is $1.35 to $3.71.
Lending Club Corp. (NYSE: LC) was raised to Buy from Neutral with a $16 price target (versus a $12.81 close) at Sterne Agee CRT. Lending Club has a consensus target price closer to $20 and a 52-week range of $10.28 to $29.29.
Perrigo Co. PLC (NYSE: PRGO) was started as Neutral with a $165 price target (versus a $153.50 close) at JPMorgan. Perrigo has a consensus price target of roughly $199 and a 52-week range of $140.40 to $215.73.
Other key analyst upgrades and downgrades seen on Wednesday were in the following:
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) was started as Perform with a $119 price target (versus a $107.32 close) at Oppenheimer.